C15182; CCI-779; NSC 683864; TeMsiroliMus (CCI-779, Torisel); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; temsirolimus 162635-04-3; TeMsiroliMus (Torisel); CS-442; rapaMycin 42-ester with 3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionic acid; CCL-779; TeMsiroliMus (~); Torisel; [14C]-Temsirolimus; Propanoic acid, 3-hydroxy-2-(hydroxymethyl)-2-methyl-, (1R,2R,4S)-2-methoxy-4-[(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,26R,27R,34aS)-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontin-3-yl]propyl]cyclohexyl ester; Rapamycin (42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]; Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate; (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; (1R,2R,4S)-4-{(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-Dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate;
,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; (1R,2R,4S)-4-{(2S)-2-[(1R,9S,12S,15R,16Z,18S,19S,21R,23S,24Z,26Z,28Z,30S,32S,35R)-1,18-Dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04
Propanoic acid, 3-hydroxy-2-(hydroxymethyl)-2-methyl-, (1R,2R,4S)-2-methoxy-4-[(2S)-2-[(3S,6R,7Z,9S,10S,12R,14S,15Z,17Z,19Z,21S,23S,26R,27R,34aS)-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31
,32,33,34,34a-tetracosahydro-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontin-3-yl]propyl]cyclohexyl ester; 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate] rapamycin; triaconta-16,24,26,28-tetraen-12-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate; (1R,2R,4S)-4-{(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24Z,30S,32S,35R)-1,18-Dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexa
Propanoic acid, 3-hydroxy-2-(hydroxymethyl)-2-methyl-, (1R,2R,4S)-2-methoxy-4-[(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15Z,21S,23S,26R,27R,34aS)-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,3
4,34a-tetracosahydro-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontin-3-yl]propyl]cyclohexyl ester; MFCD00934421; (1R,2R,4R)-4-{(2R)-2-[(1R,9S,12S,15R,16Z,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04
Propanoic acid, 3-hydroxy-2-(hydroxymethyl)-2-methyl-, (1R,2R,4R)-2-methoxy-4-[(2R)-2-[(3S,6R,7Z,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31
,32,33,34,34a-tetracosahydro-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontin-3-yl]propyl]cyclohexyl ester;
更多
警示词
危险
危险性描述
H360 可能对生育能力或胎儿造成伤害。
H410 对水生生物毒性极大并具有长期持续影响。
防范说明
AI简介：上海源叶生物科技有限公司成立于2009年，专注于生化试剂、标准品、小分子抑制剂等产品的研发与销售，服务于科研机构、工业、医疗等领域，以丰富的产品种类和优质服务著称。
